Clinical trial · Interventional
A Randomized Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy
NCT00359320CI-TRIAL-00089248terminatedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Terminated by IRB
Summary
Brief summary (as posted)
The purpose of this trial is to determine whether a mucosa-to-mucosa technique of pancreaticojejunostomy will improve the pancreatic fistula rate.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Biliary Tract Neoplasms | — | UNRESOLVED | — |
| Duodenal Neoplasms | Duodenal Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Pancreatic Neoplasms | Pancreatic Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Pancreatitis, Chronic | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| pancreaticojejunostomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Mucosa-to-jejunal mucosa technique of pancreaticojejunosto
- description
- Determine whether a duct mucosa-to-jejunal mucosa technique of pancreaticojejunostomy will improve the pancreatic fistula rate
- interventionNames
- Procedure: pancreaticojejunostomy
Primary outcomes (1)
- measure
- The primary endpoint will be the pancreatic fistula rate.
- timeFrame
- 1 year
Secondary outcomes (5)
- measure
- Length of hospitalization
- timeFrame
- 1 year
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients must have undergone pancreaticoduodenectomy. * Must have pancreatic remnant remaining in place (body and tail). * Must be candidate for reconstruction by pancreaticojejunostomy by one of the two techniques described below. * Must have an identifiable pancreatic duct which can be used for a duct-to-mucosa anastomosis. Exclusion Criteria: * Patients undergoing total pancreatectomy. * Patients undergoing PD who have had previous left-sided pancreatic resection. * Failure to sign informed consent. * Failure to identify the pancreatic duct. * Pregnant patients.
References
Publications (1)
- DERIVEDBerger AC, Howard TJ, Kennedy EP, Sauter PK, Bower-Cherry M, Dutkevitch S, Hyslop T, Schmidt CM, Rosato EL, Lavu H, Nakeeb A, Pitt HA, Lillemoe KD, Yeo CJ. Does type of pancreaticojejunostomy after pancreaticoduodenectomy decrease rate of pancreatic fistula? A randomized, prospective, dual-institution trial. J Am Coll Surg. 2009 May;208(5):738-47; discussion 747-9. doi: 10.1016/j.jamcollsurg.2008.12.031. PMID 19476827